Table 1.
Baseline Characteristics of All Patients at the Initial Study Visit
| Characteristic | N = 16 |
|---|---|
| Age, yr | 53.0 (44.0–60.0) |
| Sex, F, n (%) | 10 (62.5) |
| Asthma onset age, yr | 43.0 (27.0–56.3) |
| Body weight, kg | 56.4 (49.6–59.6) |
| Body mass index, kg/m2 | 21.4 (20.5–23.0) |
| Smoking status, never/past/current, n (%) | 8 (50.0)/6 (37.5)/2 (12.5) |
| Maintenance prednisolone, n (%) | 3 (18.8) |
| Oral prednisolone daily dose, mg/d, n = 3 | 2.5/2.5/7.0 |
| Inhaled corticosteroid, n (%) | 16 (100) |
| Inhaled corticosteroid (fluticasone equivalent) dose, μg/d | 655.0 (492.5–1,000.0) |
| Maintenance long-acting β-agonist, n (%) | 16 (100) |
| Maintenance leukotriene receptor antagonist, n (%) | 16 (100) |
| One or more exacerbations during 12 mo before enrollment, n (%) | 3 (18.8) |
| One or more hospitalizations during 12 mo before enrollment, n (%) | 0 (0) |
| Status of sinus surgery and polypectomy | |
| History of sinus surgery and polypectomy, n (%) | 7 (43.8) |
| Median number of lifetime nasal polyp surgeries | 0 (0–1.0) |
| Median time since last nasal polyp surgery, yr | 5.0 (3.5–10.5) |
| ACQ-6 | 0.8 (0.3–2.6) |
| ACT | 20.5 (14.5–24.5) |
| Peripheral eosinophil count per microliter | 370.0 (270.0–530.0) |
| Total serum IgE, IU/ml | 169.0 (45.5–482.8) |
| Omalizumab dose, mg/mo | 300 (150–600) |
| FEV1% predicted | 104.4 (92.7–112.0) |
| FEV1/FVC% | 75.2 (69.6–78.5) |
| FVC% predicted | 118.6 (111.2–128.0) |
| FEF25–75% (%) | 56.8 (43.5–70.7) |
| FeNO, ppb | 22.0 (17.1–31.0) |
Definition of abbreviations: ACQ-6 = Asthma Control Questionnaire-6; ACT = Asthma Control Test; FEF25–75 = forced expiratory flow, midexpiratory phase; FeNO = fractional exhaled nitric oxide.
Data are presented as medians and interquartile ranges unless otherwise indicated.